Immune checkpoint inhibitor-induced bullous pemphigoid: a systematic review of clinical characteristics and outcomes based on case reports
Authors:
Open Access
- 4 March 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1745011
Abstract
Objective: Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a rare and complex cutaneous immune-related adverse event (cirAE) that often impacts the continuation of ICI therapy. Currently, there are no prospective clinical studies addressing the optimal management of BP alongside ICI continuation, with existing evidence largely derived from case reports or series. This study systematically analyzes published case reports and series to compile evidence regarding the management of ICI-BP and ICI rechallenge, aiming to inform clinical practice. Methods: A comprehensive search of the PubMed, Embase, and Web of Science Core Collection (WoS CC) databases was conducted from their inception to identify eligible case reports and series. Relevant data were extracted using a standardized form. A total of 116 cases from 89 publications were included in the analysis. Results: There was no discernible disparity in the final response rate between patients with mild and severe BP (p > 0.05); however, the percentage of severe patients undergoing escalation therapy was notably higher (p < 0.001). This suggests that employing an active treatment approach based on disease severity effectively ameliorated the potentially graver prognosis in severe cases. Following BP management, 18 patients underwent rechallenge with ICI therapy, with an overall low BP recurrence rate (22.2%), indicating that most patients tolerated the resumption well. Nevertheless, the majority of relapses transpired in patients with initial severe BP, with mucosal invasion, and those who restarted the original therapy, pointing to an elevated risk in this cohort. The 11 deceased patients constituted a high-risk subset distinguished by advanced age (median 74 years), a prevalence of melanoma, and severe BP. The duration from BP diagnosis to demise was briefer in this subset (median 3.7 months), with half of the patients succumbing within 4 months. Conclusion: ICI-BP is usually manageable through a stepwise therapeutic approach, and resuming ICI treatment after lesion remission is generally possible. Clinical decision-making must be tailored to the individual patient. Caution and careful monitoring are essential when reinitiating ICI in patients who initially presented with severe disease or mucosal involvement. For elderly patients, those with melanoma, and individuals experiencing severe BP, heightened vigilance is necessary concerning short-term prognostic risks. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251172315Keywords
Funding Information
- National Key Research and Development Program of China
- National Institutes of Natural Sciences
This publication has 107 references indexed in Scilit:
- Oxidative stress impairs the expansion of regulatory T cells in active vitiligo via dysregulated CGRP-RAMP1-Gαi3 signalingFree Radical Biology and Medicine, 2025
- Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell CancersJAMA Oncology, 2025
- Pembrolizumab‐Associated Bullous Pemphigoid with Laryngeal InvolvementThe Laryngoscope, 2024
- Association of bullous pemphigoid and Grover disease induced by immune checkpoint therapyAnais Brasileiros de Dermatologia, 2024
- Interventions for bullous pemphigoidCochrane Database of Systematic Reviews, 2023
- Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With CancerJAMA Dermatology, 2022
- Immune checkpoint inhibitor–induced bullous pemphigoid: Towards a new class of drug-drug interaction?European Journal of Cancer, 2020
- Pembrolizumab‐induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patientClinical Case Reports, 2019
- Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapyEuropean Journal of Cancer, 2018
- Rituximab Treatment of Nivolumab-Induced Bullous PemphigoidJAMA Dermatology, 2017